Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
174.10
+1.60 (0.93%)
At close: Dec 12, 2025, 4:00 PM EST
172.34
-1.76 (-1.01%)
After-hours: Dec 12, 2025, 7:57 PM EST
Biogen Revenue
Biogen had revenue of $2.53B in the quarter ending September 30, 2025, with 2.79% growth. This brings the company's revenue in the last twelve months to $10.07B, up 4.77% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.07B
Revenue Growth
+4.77%
P/S Ratio
2.53
Revenue / Employee
$1,323,590
Employees
7,605
Market Cap
25.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
| Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
| Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
| Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
| Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
| Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
| Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
| Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
| Dec 31, 2010 | 4.72B | 339.08M | 7.75% |
| Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
| Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
| Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
| Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
| Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BIIB News
- 4 days ago - Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada - Business Wire
- 4 days ago - “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List - GlobeNewsWire
- 8 days ago - Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
- 8 days ago - Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - GlobeNewsWire
- 9 days ago - Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF - GlobeNewsWire
- 10 days ago - Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - GlobeNewsWire